Find comprehensive information on Myeloma diagnosis, including ICD-10 codes, clinical documentation improvement tips, healthcare guidelines, and treatment protocols. Learn about Myeloma staging, symptoms, and diagnostic criteria. Explore resources for medical coding and billing related to Myeloma, plasma cell neoplasms, and related hematologic malignancies. This resource supports healthcare professionals in accurate and efficient documentation and coding for optimal patient care.
Also known as
Multiple myeloma
Malignant neoplasm of plasma cells.
Plasma cell leukemia
Leukemic counterpart of multiple myeloma.
Other plasma cell neoplasms
Includes solitary plasmacytoma and extraosseous plasmacytoma.
Waldenstrom macroglobulinemia
Type of lymphoma associated with overproduction of IgM antibodies.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the myeloma plasma cell myeloma?
Yes
Is the plasma cell myeloma multiple?
No
Is it an extraosseous plasmacytoma?
When to use each related code
| Description |
|---|
| Cancer of plasma cells in bone marrow |
| Precursor to multiple myeloma |
| Plasma cell disorder with only one area of bone involvement |
Coding C90.00 without documented subtype (e.g., IgA, IgG) leads to DRG misclassification and lost revenue.
Incorrectly coding C90.00 when C91.50 (Plasma cell leukemia) is present can impact severity and reimbursement.
Missing documentation of myeloma stage (e.g., ISS, R-ISS) hinders accurate coding for risk adjustment and quality reporting.
Patient presents with complaints consistent with possible multiple myeloma, including bone pain, fatigue, and recurrent infections. Review of systems reveals weakness, anemia symptoms, and potential renal insufficiency. Physical examination may demonstrate tenderness to palpation over affected bones. Laboratory findings indicate elevated serum protein electrophoresis with M-protein spike, Bence Jones proteinuria, and hypercalcemia. Complete blood count shows normocytic normochromic anemia. Bone marrow biopsy confirms clonal plasma cell proliferation exceeding 10 percent. Skeletal survey reveals lytic bone lesions. Diagnostic criteria for multiple myeloma are met based on the International Myeloma Working Group IMWG criteria. Differential diagnosis includes monoclonal gammopathy of undetermined significance MGUS, smoldering myeloma, and plasmacytoma. Treatment plan includes discussion of risks and benefits of various treatment options such as chemotherapy, targeted therapy including proteasome inhibitors and immunomodulatory drugs, stem cell transplant, and supportive care for bone health and renal function. Patient education provided regarding myeloma diagnosis, prognosis, treatment options, and potential complications. Referral to hematologyoncology specialist initiated. Follow-up scheduled to monitor disease progression and treatment response. ICD-10 code C90.00, multiple myeloma not otherwise specified, is assigned.